Fatality | Jotup

Texas Department of Transportation Selects Woolpert for $3M Traffic Engineering and ITS Services Contract

Retrieved on:

Wednesday, March 20, 2024

ITS, Bicycle, Transport, Pedestrian, Death, Brigham, BPAC, Accident, Injury, Lighting, Engineering, Fatality, Road

AUSTIN, Texas, March 20, 2024 /PRNewswire-PRWeb/ -- The Texas Department of Transportation has selected Woolpert to provide traffic engineering and intelligent transportation systems services under a five-year, $3 million contract supporting its Austin, Beaumont, and Fort Worth districts.

Key Points:

AUSTIN, Texas, March 20, 2024 /PRNewswire-PRWeb/ -- The Texas Department of Transportation has selected Woolpert to provide traffic engineering and intelligent transportation systems services under a five-year, $3 million contract supporting its Austin, Beaumont, and Fort Worth districts.
Under this contract, we will be working closely with the Texas Department of Transportation to provide traffic safety analyses and other traffic engineering-related safety studies and designs to provide countermeasures for intersection crashes and other preventable accidents.
Woolpert will provide services supporting safety-related projects, including speed zone studies, traffic signal studies, traffic impact studies, safety analysis, traffic signal design, and ITS planning studies, design, and specifications development.
"Under this contract, we will be working closely with the Texas Department of Transportation to provide traffic safety analyses and other traffic engineering-related safety studies and designs to provide countermeasures for intersection crashes and other preventable accidents."

Flight Safety Foundation Annual Report Highlights Threat to Aviation Safety from Eroding Safety Culture

Retrieved on:

Monday, March 11, 2024

Flight Safety Foundation, ASN, Safety, Accident, Database, Fatality, Airline

"Complacency is a stealthy threat that can erode safety and quality unless it is actively countered with a robust safety culture.

Key Points:

"Complacency is a stealthy threat that can erode safety and quality unless it is actively countered with a robust safety culture.
Complacency can lead to shortcuts, degradation of quality, neglect of procedures, poor communication, and a delayed response to escalating risks.
Failing to rigorously reinforce a strong safety culture can become the weakest link in the safety chain."
The 2023 Safety Report is available on the Foundation Website, or by clicking here .

ESFI Receives Two Awards at the 2024 IEEE Electrical Safety Workshop

Retrieved on:

Thursday, March 7, 2024

ESW, Workplace, Fire, Data collection, IAS, Fatality, The Human Factor, Death, Young, Safety, Organization, Electronics, Electricity, IEEE, Workforce, Research, Nursing

TUCSON, Ariz., March 07, 2024 (GLOBE NEWSWIRE) -- The Electrical Safety Foundation (ESFI) was awarded an Industry of Electrical and Electronics Engineers (IEEE) 2023 Electrical Safety Workshop (ESW) Young Professional Achievement Award and Honorable Mention Paper Award for 2024.

Key Points:

TUCSON, Ariz., March 07, 2024 (GLOBE NEWSWIRE) -- The Electrical Safety Foundation (ESFI) was awarded an Industry of Electrical and Electronics Engineers (IEEE) 2023 Electrical Safety Workshop (ESW) Young Professional Achievement Award and Honorable Mention Paper Award for 2024.
The IEEE ESW was established in 1991 by the IEEE’s Industry Application Society (IAS) to bring change to electrical safety culture by helping to prevent workplace injuries occurring from electrical hazards.
In its third year, the Young Professional Achievement Award, “recognizes an individual who has demonstrated outstanding service, dedication, implementation, or promotion of electrical safety in their organizations or through contributions to the objectives of the IEEE IAS Electrical Safety Committee.” ESFI’s Program Manager, Daniel Majano, was nominated for this award because of his efforts in compiling ESFI’s workplace electrical safety data to help improve workplace electrical safety throughout the workforce.
ESFI invites all communities to utilize our free materials to help improve the safety of your workplace to prevent future electrical injuries from occurring.”

Cemtrex Announces Beta Release of Pioneering AI Gun Detection Feature

Retrieved on:

Wednesday, March 6, 2024

Hospital, Violence, Person, Record, Calendar, Fatality, Homicide, School, CNN, Death, Kverneland Group, Organization, Artificial intelligence

The introduction of this AI feature, with full commercialization planned for the second half of 2024, is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of our customers.

Key Points:

The introduction of this AI feature, with full commercialization planned for the second half of 2024, is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of our customers.
"The early adoption and feedback through our beta release are vital in shaping a solution that truly meets societal needs.
Vicon's AI gun detection technology aims to contribute significantly to efforts to reduce gun violence and its devastating impact on communities across the nation.
The Company sees the market opportunity for this feature to be vast, ranging from schools, hospitals, government buildings, retail, to religious institutions.

Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Retrieved on:

Wednesday, February 21, 2024

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.

Key Points:

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.
, associate chief of Perinatal Mental Health and member of the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National.
Overdose and other maternal mental health conditions are taking the lives of more than twice as many women as postpartum hemorrhage, the second leading cause of maternal death.
Mental health conditions such as suicide or opioid overdose are to blame for nearly 23% of maternal deaths in America, according to reports from three dozen Maternal Morbidity and Mortality Review Committees, which are state-based organizations that review each maternal death within a year of pregnancy.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on:

Tuesday, March 12, 2024

Filtration, Vespula, Toxicity, Histamine, EAACI, Immunotherapy, Asthma, Report, Allergy, Skin, Pregnancy, PR, EEC, MITES, RNA, Criterion, History, CMR, Contraindication, HEP, Draft, Guideline, Patient, Ames test, Diagnosis, Dermatitis, Venom, Literature, Trial of the century, Reproduction, Silicon–germanium, SPT, Food allergy, Cosmetics, EECS, Absorption, Marketing, Safety, Data collection, Directive 2001/83/EC, GMP, ID50, Antibody, Documentation, European, Type IV hypersensitivity, Genotoxicity, Applicant (sketch), Aeroallergen, CHMP, PRIME, Immunoglobulin G, Type, Publication, Biology, Pollen, DNA, Environment, Immune system, Toolbox, NLN, AIT, Atopic dermatitis, Fatality, Chapter, Anaphylaxis, Process validation, ICH, Antigen, Rhinitis, Clinical trial, Erythema, Knowledge, Prescription, Human, Network, Medication, Scope, VIT, ICT, EMA, Collection, Macrophage, Outline, Metabolism, Registry, Inflammation, Immunoglobulin E, Nature, European Pharmacopoeia, Food, Risk, Prevalence, Mastocytosis, Observation, Cytokine, NPP, Patient safety, Disease, Finished, Medical device

16

Key Points:

16
Guideline on allergen products development for
immunotherapy and allergy diagnosis in moderate to lowsized study populations

17

Table of contents

18

Executive summary ..................................................................................... 3

19

1.
Specific effects ................................................................................................. 17
14
15

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 2/18

53

12.
Management for allergies may involve avoidance of the allergen, medications to relieve
66

symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.
71
Recommendations are made on the clinical development, potential study designs and safety

72

considerations for allergen products within the scope of the guideline.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 3/18

88

While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

89

there is no such treatment available for type IV allergies.
93
Several guidelines applicable for allergen products are available (see section 3) and provide advice on

94

quality and clinical development according to the current knowledge.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 4/18

127

However, this guideline does not cover the indication of atopic dermatitis or asthma as these

128

conditions will require separate clinical trials (see Section 6).
129
In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

130

DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

131

substantially to the allergen products as discussed above.
1
156

?

Guideline on the clinical development of products for specific immunotherapy for the treatment

157
158

of allergic diseases - CHMP/EWP/18504/2006
?

159
160
161

Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

?

Guideline on process validation for finished products - information and data to be provided in
regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 5/18

162

?

Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

163

4.
In any
199

case, a reduced validation should include all relevant manufacturing process steps that are considered
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 6/18

200

product specific.
290
Diagnostic allergen products (Type I allergy)

291

A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

292

intracutaneous or provocation testing.
298
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 9/18

305
306

7.1.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 11/18

377

8.
Clinical development of products for AIT: Study design,
efficacy and safety
378

In general, the clinical development should be performed according to current guidelines.
In such single trial, the suitability as a test allergen as well as the
376

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 12/18

415

dose finding for the therapeutic allergen could be investigated.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 13/18

454
455

8.2.1.
493
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 15/18

527

In general, sensitivity and specificity of the product should be determined.
540
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 16/18

561

10.2.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 17/18

595

4.
Allergol Immunopathol, 1989;
602

17(2):53-65

603

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 18/18

Let’s Not Wait Until More People Die: Texas Attorney Amy Witherite Urges Caution Amid Driverless Truck Rollout

Retrieved on:

Wednesday, March 6, 2024

As companies prepare to introduce driverless trucks onto the nation’s roads, Amy Witherite, a prominent Texas attorney and founder of Witherite Law Group , is sounding the alarm on potential safety risks associated with autonomous vehicle technology.

Key Points:

As companies prepare to introduce driverless trucks onto the nation’s roads, Amy Witherite, a prominent Texas attorney and founder of Witherite Law Group , is sounding the alarm on potential safety risks associated with autonomous vehicle technology.
"As an attorney and citizen who shares the highway with these vehicles, I am genuinely concerned about safety," says Witherite.
The complexities of navigating varied environments and interacting with diverse road users make achieving reliable and safe driverless operations a formidable task.
Witherite, whose firm specializes in accidents involving the trucking industry, brings a wealth of experience and expertise to the conversation.

Production growth of 3% from focused investment in the health of our business; underlying EBITDA of $23.9 billion and full year ordinary dividend of 435 US cents per share

Retrieved on:

Wednesday, February 21, 2024

We continue to work closely with the authorities to support their efforts to understand the full facts of what happened.

Key Points:

We continue to work closely with the authorities to support their efforts to understand the full facts of what happened.
This tragedy strengthens our resolve to never be complacent about safety, so that we continue to learn and improve.
Our balance sheet strength enables us to continue to invest with discipline while also paying an ordinary dividend of $7.1 billion, a 60% payout.
As part of our focus on Best Operator, we continue to roll out the Safe Production System across our business.

5GAA, Partner Associations Issue Statement on US Department of Commerce's Inquiry into Connected Vehicles

Retrieved on:

Thursday, March 7, 2024

Bureau, Privacy, ITS America, Transport, Crash, Commerce, Fatality, Government, Security, Communication, Organization, USDOT, Pedestrian

According to the latest estimates from the National Highway Traffic Safety Administration, 42,795 people died in motor vehicle traffic crashes in 2022.

Key Points:

According to the latest estimates from the National Highway Traffic Safety Administration, 42,795 people died in motor vehicle traffic crashes in 2022.
V2X technology can also help advance climate and sustainability goals by increasing traffic flow and efficiency.
Our members have worked closely with U.S. Department of Transportation (USDOT) for several years to proactively develop a robust message security solution for V2X communications.
The United States is currently a leader in V2X innovation, but risks falling behind if the government hampers broadscale deployment.

According to Institute for Economics & Peace, Terrorism gets worse as global conflicts drive risk of new wave

Retrieved on:

Thursday, February 29, 2024

JNIM, Violence, MENA, Hamas, Al-Qaeda, Suicide, Death, Injury, Hostage, Terrorism, Peace, Record, Fatality, Risk, Crime, Data, Homicide, Islam, Conflict, Map, Hezbollah, Global Peace Index, Economics, IEP, Unemployment, GTI, Al-Shabab

Over 90% of terrorist attacks and 98% of terrorism deaths in 2023 occurred in conflict zones, underscoring the strong link between conflict and terrorism.

Key Points:

Over 90% of terrorist attacks and 98% of terrorism deaths in 2023 occurred in conflict zones, underscoring the strong link between conflict and terrorism.
The Global Terrorism Index 2024 (GTI) highlights that terrorism remains a serious global threat, with total deaths from terrorism increasing by 22% to 8,352 in 2023, now at their highest since 2017.
The GTI is produced by the leading international think tank the Institute for Economics & Peace (IEP) and has been published annually for the last eleven years.
The report ranks 163 countries (99.7 % of the world's population) according to the impact of terrorism.